Pharma CFCII’s Director provides us with an overview of the services offered to French and Italian companies by the Chamber, as well as her perceptions about investments between the two countries, and her optimism about Italy’s return to economic growth. Ms Zanardi, you have been at the head of the CFCII…
Pharma The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws. He also discusses the issues of maintaining the sustainability of the French healthcare budget and the importance of increasing European…
innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients. You have had…
regulation The executive director of the board bringing together multinational and local drug manufacturers talks about the chamber’s goal to position the pharmaceutical industry as the most important manufacturing sector in Mexico, how the chamber is working with the government and its membership to reach this goal and which new dynamics are…
regulation Carlos Chiale, National Administrator of ANMAT, discusses the agency’s latest strategy implementation and its pioneering work in the area of fighting drug falsification. Could you provide a historical overview of ANMAT, its main achievements and current activities today? Since its creation in 1992, ANMAT has performed activities intended for…
See our Cookie Privacy Policy Here